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Predictors of Intramyocardial Hemorrhage After Reperfused
ST-Segment Elevation Myocardial Infarction
Raquel P. Amier, MD;* Ruben Y. G. Tijssen, MD;* Paul F. A. Teunissen, MD, PhD; Rodrigo Fernandez-Jimenez, MD; Gonzalo Pizarro, MD,
PhD; Ines Garcıa-Lunar, MD; Teresa Bastante, MD; Peter M. van de Ven, PhD; Aernout M. Beek, MD, PhD; Martijn W. Smulders, MD;
Sebastiaan C. A. M. Bekkers, MD, PhD; Niels van Royen, MD, PhD; Borja Ibanez, MD, PhD; Robin Nijveldt, MD, PhD
Background-—Findings from recent studies show that microvascular injury consists of microvascular destruction and
intramyocardial hemorrhage (IMH). Patients with ST-segment elevation myocardial infarction (STEMI) with IMH show poorer
prognoses than patients without IMH. Knowledge on predictors for the occurrence of IMH after STEMI is lacking. The current study
aimed to investigate the prevalence and extent of IMH in patients with STEMI and its relation with periprocedural and clinical
variables.
Methods and Results-—A multicenter observational cohort study was performed in patients with successfully reperfused STEMI
with cardiovascular magnetic resonance examination 5.51.8 days after percutaneous coronary intervention. Microvascular injury
was visualized using late gadolinium enhancement and T2-weighted cardiovascular magnetic resonance imaging for microvascular
obstruction and IMH, respectively. The median was used as the cutoff value to divide the study population with presence of IMH
into mild or extensive IMH. Clinical and periprocedural parameters were studied in relation to occurrence of IMH and extensive
IMH, respectively. Of the 410 patients, 54% had IMH. The presence of IMH was independently associated with anterior infarction
(odds ratio, 2.96; 95% CI, 1.73–5.06 [P<0.001]) and periprocedural glycoprotein IIb/IIIa inhibitor treatment (odds ratio, 2.67; 95%
CI, 1.49–4.80 [P<0.001]). Extensive IMH was independently associated with anterior infarction (odds ratio, 3.76; 95% CI, 1.91–
7.43 [P<0.001]). Presence and extent of IMH was associated with larger infarct size, greater extent of microvascular obstruction,
larger left ventricular dimensions, and lower left ventricular ejection fraction (all P<0.001).
Conclusions-—Occurrence of IMH was associated with anterior infarction and glycoprotein IIb/IIIa inhibitor treatment. Extensive
IMH was associated with anterior infarction. IMH was associated with more severe infarction and worse short-term left ventricular
function in patients with STEMI. ( J Am Heart Assoc. 2017;6:e005651. DOI: 10.1161/JAHA.117.005651.)
Key Words: acute myocardial infarction • cardiac magnetic resonance • intramyocardial hemorrhage • percutaneous coronary
intervention • ST-segment elevation myocardial infarction
T he recommended treatment for ST-segment elevationmyocardial infarction (STEMI) is coronary revasculariza-
tion by primary percutaneous coronary intervention (PCI) in
combination with antithrombotic therapy.1 PCI and coronary
revascularization, however, can cause additional injury in the
form of reperfusion arrhythmias, myocardial stunning, and
microvascular injury. Microvascular injury, also known as the
no-reﬂow phenomenon, occurs in up to 40% of patients after
successful PCI2 and may include microvascular obstruction
(MVO) and intramyocardial hemorrhage (IMH) as visualized by
cardiac magnetic resonance (CMR) imaging.3 Restoration of
blood ﬂow to infarcted or ischemic myocardium inadvertently
leads to ultrastructural and functional changes at the
microvascular level, including microvascular plugging, platelet
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aggregation, microvascular spams, inﬂammatory response,
and ischemic and reperfusion damage to the endothelium.4,5
Recently, it was shown that these areas of microvascular
injury mainly contain areas of microvascular destruction, but
also extensive erythrocyte extravasation referred to as
reperfusion-induced IMH.6–8
Although microvascular injury and IMH are closely related,
it is unclear which factors determine why IMH occurs in
certain patients with microvascular injury. IMH might be a
feature of larger infarction; however, large infarctions occur
without microvascular injury as well, thus patient-related and
periprocedural factors are hypothesized to play a role. Recent
studies have linked the presence of IMH to larger infarctions
with worse left ventricular (LV) functional recovery compared
with MVO only.9–11 Clarifying which factors promote IMH will
increase our understanding of the pathophysiology and might
thereby guide future steps to improve patient outcome after
STEMI.
Visualization and quantiﬁcation of infarct characteristics
including infarct size, MVO, and IMH, are preferably performed
with CMR imaging. With late gadolinium enhancement CMR
imaging, infarcted myocardium is assessed by hyperenhance-
ment after contrast administration, and MVO can be seen as a
hypointense core within the hyperenhanced region. On T2-
weighted CMR imaging, a hypointense core within the
hyperintense edematous infarcted myocardium is thought to
reﬂect IMH caused by the paramagnetic effects of hemoglobin
breakdown products.9
The current study evaluated the prevalence and extent of
IMH and the relation of IMH with clinical and procedural
parameters in a large group of patients with revascularized
STEMI who underwent CMR imaging in the days after
infarction. In addition, the relation of IMH with infarct
characteristics and short-term LV functional outcome was
assessed.
Methods
In this observational cohort study, prospectively included
consecutive patients with STEMI who underwent CMR imag-
ing 4 to 12 days after successful treatment by primary PCI
were analyzed. Patient data were derived from previously
described cohorts of the VU University Medical Center
(PREDICT-MVI database and MVO database),12,13 Maastricht
University Medical Center (MAST database),14 and Centro
Nacional Investigaciones Cardiovasculares Carlos III (METO-
CARD-CNIC [Metoprolol in Cardioprotection During an Acute
Myocardial Infarction] and Clock database),15,16 performed
between 2003 and 2014. Written informed consent was
obtained from all patients.
Coronary Angiography
Thrombolysis in myocardial infarction (TIMI) grade 3 ﬂow post-
PCI was deﬁned as a visually normal ﬂow through the stented
coronary artery with normal distal coronary perfusion. Infarc-
tions of the left anterior descending and left main stem
coronary artery were deﬁned as anterior myocardial infarc-
tion. Findings from coronary angiograms from patients of the
METOCARD-CNIC database were adjudicated by an indepen-
dent clinical events committee.
Cardiovascular Magnetic Resonance
The designs of the CMR protocols of all cohorts were
previously published.12–14,17 Patients underwent CMR imag-
ing 5.51.8 days after PCI, using a 1.5- or 3.0-Tesla clinical
magnetic resonance scanner (1.5-T Sonata or Avanto [Sie-
mens] or 1.5-T Intera or 3.0-T Achieva [Philips Medical
Systems]).
In summary, balanced steady-state free precession cine
imaging was performed in standard long- and short-axis
orientations to measure LV volumes and calculate LV ejection
fraction. Typical parameters were in-plane resolution
1.692.0 mm; slice thickness/slice gap: 5/5 mm, 6/4 mm,
8/0 mm; ﬂip angle 40 to 75°; temporal resolution 35 to
50 ms; and TR/TE 3.4/1.7. Prior to contrast administration,
breath-hold T2-weighted spin-echo images were acquired to
visualize infarct-related edema and IMH in short-axis orienta-
tion covering the whole left ventricle or infarcted area only
(deﬁned using 3 long-axis views of T2-weighted CMR imag-
ing).9 Typical parameters were TR=29 RR interval; TE 64 ms;
and voxel size 1.591.897 mm. IMH was deﬁned as an area
with low (attenuated) signal within the hyperintense
Clinical Perspective
What is New?
• This is the ﬁrst study to link periprocedural additional
glycoprotein IIb/IIIa inhibitor treatment to higher occur-
rence of intramyocardial hemorrhage in patients with
reperfused ST-segment elevation myocardial infarction.
What are the Clinical Implications?
• The optimal application of aggressive antithrombotic ther-
apies in patients with ST-segment elevation myocardial
infarction undergoing percutaneous coronary intervention
remains to be studied, especially in the era of adequate
double antiplatelet preloading.
• Anterior infarct location predicted presence and severity of
intramyocardial hemorrhage and may prove useful in direct
risk stratiﬁcation.
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edematous myocardium and was manually delineated and
quantiﬁed. All IMH analyses were performed by a trained
researcher (R.T.), and were later controlled by experienced
readers (R.N. or R.F.J.). Measurements of IMH were performed
blinded to clinical and other CMR imaging data. In case of
disagreement, consensus was reached between the readers.
Late gadolinium enhancement imaging was performed using
an inversion recovery gradient echo sequence 10 to 15 min-
utes after administration of 0.2 mmol/kg gadolinium-based
contrast agent (Magnevist [Schering] or Dotarem [Guerbet]) in
short-axis orientation covering the whole left ventricle. Typical
parameters were in-plane resolution 1.591.5 mm; slice
thickness 5 to 8 mm; TR 3.9 to 9.6 mm; TE 2.4 to 4.4 ms;
ﬂip angle 25°; and TI 250 to 350 ms nulled to normal
myocardium. Infarct size was measured using the full-width
half maximum method. Areas of hypoenhancement within the
hyperenhanced infarcted myocardium were manually delin-
eated and considered MVO. For quantiﬁcation purposes,
areas of MVO were included in the total infarct size.13 LV
dimensions were indexed to body surface area, which was
calculated using the formula of DuBois and DuBois. All CMR
data were analyzed using dedicated ofﬂine software
(QMassMR version 7.6, Medis).
Statistical Methods
All patient data were merged into 1 data set. Continuous
variables are presented as mean and SD or median and
interquartile range (IQR) when appropriate. Categorical vari-
ables are presented as number and percentage. We deter-
mined skewness and kurtosis and used Shapiro–Wilk test, box
plots, stem-and-leaf plots, and histograms to explore the
distribution of continuous variables. In addition to the
presence of IMH, the extent of IMH was analyzed. Because
of a right-skewed and zero-inﬂated distribution of IMH extent,
patients were categorized into 3 groups: no IMH, mild IMH,
and extensive IMH. Extensive versus mild IMH was deﬁned as
IMH weighing more versus equal/less than the median
(3.76 g) among patients with presence of IMH, respectively.
For univariable analysis, we compared means of normally
distributed continuous variables between these groups using
one-way ANOVA with Tukey post hoc tests for the difference
between the groups. Not normally distributed continuous
variables were compared using Kruskall–Wallis ANOVA, and
post hoc testing was performed with Mann–Whitney U tests
between groups (if overall ANOVA was signiﬁcant). Between-
group comparison of categorical variables was performed
using chi-square test with post hoc testing, with chi-square
tests separate for each pair of groups (if the overall chi-square
test for 3 groups was signiﬁcant). P values of <0.05 were
considered statistically signiﬁcant. For post hoc testing for
differences between the 3 groups (no, mild, and extensive
IMH), Bonferroni correction was applied and P values of
<0.017 were considered statistically signiﬁcant. Covariates of
interest associated with the occurrence of IMH as well as
the occurrence of extensive IMH (versus mild or no IMH) were
investigated using multivariable logistic regression. All
baseline variables that were signiﬁcant at P<0.10 on
univariable logistic regression analysis were entered into a
multivariable model. All statistical analyses were performed
using IBM SPSS software package (IBM SPSS Statistics
version 22).
Results
Of 445 eligible STEMI patients, 410 patients were included in
this pooled individual patient analysis. The main reason for
exclusion was lack of or insufﬁcient quality of T2-weighted
CMR images. The mean age of the population was
5911 years, and 343 patients (84%) were men. Baseline
characteristics of the study population per study are shown in
Table 1 and baseline characteristics of the total study
population and per IMH group are shown in Table 2.
A total of 222 patients (54%) had IMH, categorized into 2
groups of 111 patients based on the median IMH (3.76 g) as
the cutoff value. Figure 1 shows typical examples of IMH as
visualized by T2-weighted CMR imaging in patients without
IMH, those with mild IMH, and those with extensive IMH.
Clinical and Periprocedural Parameters
Associated With the Presence of IMH
In univariable analysis, male sex (odds ratio [OR], 1.95; 95%
CI, 1.15–3.33 [P=0.014]), anterior infarction (OR, 4.12; 95%
CI, 2.52–6.72 [P<0.001]), lack of TIMI grade 3 ﬂow post-PCI
(OR, 1.63; 95% CI, 0.97–2.73 [P=0.066]), and treatment with
additional glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor (OR, 3.67;
95% CI, 2.13–6.30 [P<0.001]) were associated with the
presence of IMH, while age (OR, 0.98; 95% CI, 0.97–1.00
[P=0.085]) and medical history of hypertension (OR, 0.66;
95% CI, 0.45–0.99 [P=0.044]) were negatively associated with
presence of IMH. In multivariable analysis, anterior infarction
(OR, 2.96; 95% CI, 1.73–5.06 [P<0.001]) and treatment with
heparin or bivalirudin with additional GPIIb/IIIa inhibitor (OR,
2.67; 95% CI, 1.49–4.80 [P<0.001]) remained signiﬁcantly
associated with IMH (Table 3).
To investigate whether these results were driven by the 2
patient cohorts from CNIC, in which only patients with
anterior infarction were included and >85% received GPIIb/IIIa
inhibitor treatment, the univariable and multivariable analyses
were repeated without these patients. In multivariable anal-
ysis without the METOCARD and Clock patients, both anterior
infarction (OR, 3.29; 95% CI, 1.62–6.70 [P=0.001]) and
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additional GPIIb/IIIa inhibitor (OR 4.14; 95% CI, 1.81–9.45
[P=0.001]) remained signiﬁcantly associated with IMH.
Clinical and Periprocedural Parameters
Associated With Extensive IMH
The association of extensive IMH with clinical and periproce-
dural variables was investigated by comparing patients with
extensive IMH with patients with mild or no IMH. In univariable
analysis, male sex (OR, 1.86; 95% CI, 0.96–3.62 [P=0.068]) and
anterior infarction (OR, 3.85; 95% CI, 1.97–7.54 [P<0.001])
were associated with extensive IMH, while age (OR, 0.98; 95%
CI, 0.96–1.00 [P=0.047]) and hypertension (OR, 0.55; 95% CI,
0.34–0.87 [P=0.012]) were negatively associated with exten-
sive IMH. In multivariable analysis, anterior infarction (OR,
3.76; 95% CI, 1.91–7.43 [P<0.001]) remained signiﬁcantly
associated with extensive IMH, and hypertension (OR, 0.60;
95% CI, 0.37–0.99 [P=0.045]) remained signiﬁcantly negatively
associated with extensive IMH (Table 4).
Analogous to the previous prediction model, these analy-
ses were repeated without the METOCARD and Clock
patients, for abovementioned reasons. In multivariable anal-
ysis without the METOCARD and Clock patients, anterior
infarction (OR, 4.50; 95% CI, 1.92–10.53 [P=0.001]) remained
signiﬁcantly associated with extensive IMH.
Furthermore, subanalysis was performed in all patients to
assess whether extensive IMH was associated with medical
therapy before hospital admission. In univariable analysis,
statin treatment (OR, 0.33; 95% CI, 0.14–0.75 [P=0.008]) was
negatively associated with extensive IMH. After correction
for age and sex, no signiﬁcant relation remained for statin
treatment and extensive IMH.
Association Between IMH and CMR Parameters
CMR examinations were performed at 5.51.8 days after
PCI, similar for patients with and without IMH. Figure 2
shows that IMH occurred already in the very early phase after
STEMI and is detectable with CMR imaging as soon as 1 to
2 days post-PCI. Infarct size, MVO, and LV functional
parameters were compared between the 3 patient groups,
ie, no IMH, mild IMH, and extensive IMH. The relationship of
CMR parameters of infarct severity and short-term LV
functional outcome with the extent of IMH are shown in
Table 5.
MVO was seen on late gadolinium enhancement CMR
imaging in 279 patients (69%), and IMH was seen on T2-
weighted CMR imaging in 222 patients (54%). Fifty-seven
patients (14%) showed MVO without IMH and no patients
showed IMH without MVO; late gadolinium enhancement CMR
Table 1. Baseline Characteristics Per Study Population
Patients With
STEMI (n=410)
PREDICT-MVI
(n=49)
MVO
(n=50)
MAST
(n=74)
Clock
(n=22)
METOCARD-CNIC
(n=215)
Age, y 58.5 (10.8) 60.4 (9.1) 56.9 (10.1) 59.2 (11.2) 57.1 (7.3) 58.4 (11.5)
Male sex, No. (%) 343 (84) 37 (76) 44 (88) 57 (77) 17 (77) 188 (87)
BMI 27.1 (3.5) 27.4 (3.5) 25.6 (2.6) 27.4 (9.6) 27.5 (3.8) 27.6 (3.6)
Hypertension, No. (%) 163 (40) 38 (78) 13 (26) 24 (33) 6 (29) 82 (39)
Diabetes mellitus, No. (%) 60 (15) 7 (14) 1 (2) 5 (7) 5 (24) 42 (20)
Hypercholesterolemia, No. (%) 143 (37) 8 (16) 16 (32) 24 (42) 8 (38) 87 (41)
Smoking, No. (%) 318 (78) 41 (84) 33 (66) 65 (88) 16 (76) 163 (77)
Anterior infarction, No. (%) 303 (75) 27 (55) 30 (60) 20 (27) 22 (100) 204 (98)
Time to reperfusion, h 3.0 (2.3–3.9) 2.3 (1.9–2.9) 2.5 (2.0–4.0) 3.3 (2.5–4.2) 3.5 (2.2–6.7) 3.0 (2.4–3.7)
TIMI 3 post-PCI, No. (%) 333 (82) 46 (94) 42 (84) 66 (92) 20 (91) 159 (74)
Aspirin, No. (%) 389 (97) 36 (84) 50 (100) 74 (100) 20 (100) 209 (98)
P2Y12 inhibitors, No. (%) 397 (99) 49 (100) 50 (100) 69 (97) 19 (95) 210 (99)
Antithrombotic therapy PCI
Heparin only, No. (%) 74 (19) 1 (2) 8 (16) 42 (58) 3 (15) 20 (9)
Bivalirudin only, No. (%) 28 (7) 27 (64) 0 (0) 0 (0) 0 (0) 1 (1)
Additional GPIIb/IIIa inhibitor with heparin
or bivalirudin, No. (%)
298 (74) 14 (33) 42 (84) 31 (43) 17 (85) 194 (90)
Data are presented as number (percentage) for dichotomous variables, meanSD for normally distributed continuous variables, and median (interquartile range) for non-normally
distributed continuous variables. BMI indicates body mass index; GPIIb/IIIa inhibitor, glycoprotein IIb/IIIa inhibitor; MVO, microvascular obstruction; PCI, percutaneous coronary
intervention; STEMI, ST-segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction. Study acronyms are explained in the Methods section.
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imaging was not available in 5 patients, all of whom showed
no IMH.
Patients with extensive IMH had larger absolute and
indexed infarct size compared with patients with mild or
no IMH (all P<0.001). The extent of MVO, both absolute
and indexed to LV mass, was signiﬁcantly larger in
patients with extensive IMH compared with mild or no
IMH (both P<0.01). Furthermore, patients with extensive
IMH had lower LV ejection fraction and larger LV
dimensions, both absolute and indexed to body surface
area, compared with patients with mild or no IMH (all
P<0.001).
Table 2. Baseline Characteristics Per IMH Group
Patients With
STEMI (n=410)
No IMH
(n=188)
Mild IMH
(n=111)
Extensive IMH
(n=111) P Value
Age, y 58.5 (10.8) 59.5 (10.6) 58.6 (10.4) 56.7 (11.4) 0.11
Male sex, No. (%) 343 (84) 148 (79) 96 (87) 99 (89) 0.039
BMI 27.1 (3.5) 27.0 (3.8) 27.0 (3.3) 27.3 (3.2) 0.76
Hypertension, No. (%) 163 (40) 85 (46) 45 (41) 33 (30) 0.031
Diabetes mellitus, No. (%) 60 (15) 29 (15) 20 (18) 11 (10) 0.21
Hypercholesterolemia, No. (%) 143 (37) 61 (35) 49 (45) 33 (31) 0.083
Smoking, No. (%) 318 (78) 144 (77) 85 (77) 89 (81) 0.71
Anterior infarction, No. (%) 303 (75) 114 (61) 92 (84) 97 (90) <0.001
Time to reperfusion, h 3.0 (2.3–3.9) 3.0 (2.3–3.9) 3.1 (2.4–4.1) 2.8 (2.2–3.7) 0.16
TIMI 3 post-PCI, No. (%) 333 (82) 159 (86) 88 (79) 86 (78) 0.17
Aspirin, No. (%) 389 (97) 176 (97) 109 (98) 104 (96) 0.69
P2Y12 inhibitors, No. (%) 397 (99) 184 (100) 109 (98) 104 (96) 0.29
Antithrombotic therapy PCI, No. (%) <0.001
Heparin only 74 (19) 50 (28) 8 (7) 16 (15)
Bivalirudin only 28 (7) 22 (12) 3 (3) 3 (3)
Additional GPIIb/IIIa inhibitor with heparin or bivalirudin 298 (74) 108 (60) 100 (90) 90 (83)
Data are presented as number (percentage) for dichotomous variables, meanSD for normally distributed continuous variables, and median (interquartile range) for non-normally
distributed continuous variables. P values are shown for overall difference between the patient groups (no, mild, and extensive intramyocardial hemorrhage [IMH], respectively). BMI
indicates body mass index; GPIIb/IIIa inhibitor, glycoprotein IIb/IIIa inhibitor; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIMI,
thrombolysis in myocardial infarction.
Figure 1. Typical cardiac magnetic resonance imaging examples of (A) a patient without intramyocardial hemorrhage (IMH), (B) a patient with
mild IMH, and (C) a patient with extensive IMH. IMH is visible on T2-weighted cardiovascular magnetic resonance images as a hypointense
core within the hyperintense infarcted region.
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Compared with patients without IMH, patients with mild
IMH had larger absolute and indexed infarct size (both
P<0.001), higher prevalence of MVO (P<0.001), and greater
absolute extent of MVO (P=0.001). Regarding LV functional
parameters, patients with mild IMH had lower LV ejection
fraction (P<0.001) and larger absolute and indexed LV end-
systolic volume (P=0.013 and 0.005, respectively).
To investigate whether the abovementioned relations were
driven by higher presence of anterior infarction in the patients
with IMH, the relation of CMR parameters with extent of IMH
was also assessed in patients with anterior infarction only. All
of the abovementioned relations between CMR parameters
and the extent of IMH remained intact with equal or greater
statistical signiﬁcance.
Discussion
Infarct characteristics and LV functional outcome, as
assessed by CMR imaging, are increasingly used as surrogate
outcome measures for prognosis after myocardial infarction,
even when studying the effect of new interventions. The
presence of microvascular injury, regardless of successful
epicardial revascularization, confers a poorer prognosis for
patients.9,10,18 Both MVO and IMH are features of the larger
concept of microvascular injury6–8 and have been linked to
poorer prognosis after STEMI,9,11 even independent from
infarct size.19 Moreover, the presence of IMH on top of MVO
confers an even poorer prognosis than the presence of MVO
only.10,20 Therefore, an increasing number of studies are
focusing on understanding IMH within the concept of
microvascular injury after STEMI. This study is the ﬁrst to
investigate the relation of periprocedural factors with the
presence and extent of IMH and is the largest patient series
thus far.
The main ﬁndings of the study are: (1) IMH occurs in 54%
of patients with successfully reperfused STEMI, whereas MVO
occurs in 70%; (2) the presence of IMH is independently
associated with anterior infarct location and periprocedural
administration of additional GPIIb/IIIa inhibitor; (3) extensive
IMH is independently associated with anterior infarct location;
and (4) the presence and extent of IMH are associated with
more severe infarction and worse short-term LV functional
parameters.
The most striking ﬁnding of this study is the strong
independent association of the presence of IMH with
additional GPIIb/IIIa inhibitor treatment. Although a causal
relationship cannot be assumed because of the observational
nature of the study, it is conceivable that more aggressive
antithrombotic strategies might induce IMH. Several studies
have shown modest infarct size reduction after additional
Table 3. Univariable and Multivariable Logistic Regression Analysis for Presence of IMH
Univariable Multivariable*
OR 95% CI P Value OR 95% CI P Value
Age, y 0.98 0.97–1.00 0.085 0.99 0.97–1.00 0.20
Male sex 1.95 1.15–3.33 0.014 1.39 0.76–2.57 0.29
BMI 1.01 0.96–1.07 0.65
Hypertension 0.66 0.45–0.99 0.044 0.84 0.53–1.34 0.46
Diabetes mellitus 0.90 0.52–1.57 0.72
Hypercholesterolemia 1.13 0.75–1.72 0.55
Smoking 1.13 0.71–1.81 0.61
Anterior infarction 4.12 2.52–6.72 <0.001 2.96 1.73–5.06 <0.001
Time to reperfusion, h 0.95 0.86–1.05 0.32
TIMI <3 post-PCI 1.63 0.97–2.73 0.066 1.18 0.68–2.07 0.55
Aspirin 1.01 0.30–3.36 0.99
P2Y12 inhibitors 0.23 0.03–2.00 0.18
Antithrombotic therapy PCI
Bivalirudin only (vs heparin only) 0.57 0.20–1.58 0.28 0.66 0.23–1.96 0.46
Additional GPIIb/IIIa inhibitor with heparin
or bivalirudin (vs heparin only)
3.67 2.13–6.30 <0.001 2.67 1.49–4.80 0.001
BMI indicates body mass index; GPIIb/IIIa inhibitor, glycoprotein IIb/IIIa inhibitor; IMH, intramyocardial hemorrhage; OR, odds ratio; PCI, percutaneous coronary intervention; TIMI,
thrombolysis in myocardial infarction.
*Multivariable analysis of signiﬁcant univariable parameters with P<0.10.
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GPIIb/IIIa inhibitor treatment during PCI; however results on
long-term LV functional recovery and major adverse cardiac
events remain conﬂicting21–23 and no additional mortality
reduction was shown after GPIIb/IIIa inhibitor treatment in
patients with STEMI who had adequate dual antiplatelet
preloading.24 We found additional GPIIb/IIIa inhibitor treat-
ment to be associated with higher incidence of IMH. Also,
animal models have shown increased incidence of IMH with
use of additional intracoronary GPIIb/IIIa inhibitors,25 and a
recent study in patients with STEMI showed potent inhibition
of platelet aggregation following GPIIb/IIIa inhibitors to be
related to IMH occurrence.26 We postulate that the discor-
dance of infarct size reduction without a conclusive effect on
long-term clinical outcome might partially be explained by a
higher incidence of IMH in patients treated with additional
GPIIb/IIIa inhibitors.
Anterior infarction was also independently associated with
the presence of IMH. Anterior infarctions generally lead to
poorer clinical outcome, ie, lower LV ejection fraction, higher
incidence of heart failure, and higher mortality rate compared
with inferior infarctions. Occlusion of the left main stem or left
anterior descending coronary artery often results in larger
infarctions, which in previous studies has been linked to the
presence of microvascular injury, including IMH.10,13 Never-
theless, infarct size is only known (days) after PCI when
Table 4. Univariable and Multivariable Logistic Regression Analysis for Extensive IMH (Extensive vs Mild or No IMH)
Univariable Multivariable*
OR 95% CI P Value OR 95% CI P Value
Age, y 0.98 0.96–1.00 0.047 0.98 0.96–1.00 0.11
Male sex 1.86 0.96–3.62 0.068 1.34 0.66–2.69 0.42
BMI 1.02 0.96–1.09 0.46
Hypertension 0.55 0.34–0.87 0.012 0.60 0.37–0.99 0.045
Diabetes mellitus 0.56 0.28–1.13 0.10
Hypercholesterolemia 0.70 0.44–1.13 0.14
Smoking 1.26 0.73–2.18 0.41
Anterior infarction 3.85 1.97–7.54 <0.001 3.76 1.91–7.43 <0.001
Time to reperfusion, h 0.94 0.83–1.07 0.35
TIMI <3 post-PCI 1.44 0.84–2.46 0.19
Aspirin 0.64 0.18–2.23 0.48
P2Y12 inhibitors 0.36 0.07–1.79 0.21
Antithrombotic therapy PCI
Bivalirudin only (vs heparin only) 0.44 0.12–1.63 0.22
Additional GPIIb/IIIa inhibitor with heparin or
bivalirudin (vs heparin only)
1.57 0.86–2.88 0.15
BMI indicates body mass index; GPIIb/IIIa inhibitor, glycoprotein IIb/IIIa inhibitor; IMH, intramyocardial hemorrhage; OR, odds ratio; PCI, percutaneous coronary intervention; TIMI,
thrombolysis in myocardial infarction.
*Multivariable analysis of signiﬁcant univariable parameters with P<0.10.
Figure 2. Number of patients with intramyocardial hemor-
rhage (IMH) on the days cardiovascular magnetic resonance
(CMR) imaging was performed following percutaneous coronary
intervention, illustrating that IMH occurs already in the very
early phase after ST-segment elevation myocardial infarction
(STEMI) and is detectable with CMR imaging as soon as 1 to
2 days after STEMI. Red column: patients with IMH with
percentage of total patients displayed. Blue column: patients
without IMH.
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cardiac imaging is performed, rendering it unsuitable for
immediate risk stratiﬁcation at the catheterization laboratory,
whereas infarct location is immediately revealed at the time of
the procedure (or even prior to PCI on the presenting ECG).
When designing therapies or strategies aimed at minimizing
IMH, infarct location might prove useful as part of a risk score
to directly identify high-risk patients suited for additional
therapy.
Medical history of hypertension before hospitalization was
independently associated with a lower risk of extensive IMH.
On a pathophysiological level, our results are difﬁcult to
interpret because medical history of hypertension is not a true
reﬂection of vascular exposure to hypertension, as patients
with undetected and therefore untreated hypertension are
misclassiﬁed. On the one hand, this relationship is counter-
intuitive, as hypertension has previously been linked to
coronary (micro)vascular remodeling and endothelial dysfunc-
tion.27 In addition, both hypertension and IMH have been
linked to adverse prognoses following STEMI. On the other
hand, our results might reﬂect a possible protective effect of
the medication these patients already received before hospi-
tal admission, ie, angiotensin-converting enzyme inhibitors
and statins. Subanalysis in our study showed no signiﬁcant
relationship between medical therapy before admission
(b-blocker, angiotensin-converting enzyme inhibitor, angioten-
sin receptor blocker, statin, or calcium channel blocker) and
extensive IMH, after correction for age and sex. Taking into
consideration that medical history of hypertension was not
independently associated with presence of IMH and border-
line signiﬁcantly associated with extensive IMH, we believe
this ﬁnding should be interpreted with caution.
Lastly, our results show IMH to be associated with more
severe infarction, as shown by poorer LV function, larger LV
dimensions, larger infarct size, and greater extent of MVO on
short-term CMR imaging. These results were not driven by a
higher incidence of anterior infarction in patients with IMH, as
the associations remained signiﬁcant when assessed sepa-
rately in patients with anterior infarction only. These ﬁndings
are in agreement with those from previous studies.7,11,19,20
Long-term follow-up of these patients is necessary to
investigate LV functional recovery and mortality/major
adverse cardiac events.
Limitations
Several factors leading to potential bias should be addressed.
Two studies (Clock and METOCARD) included anterior infarc-
tion only. Also, the use of additional GPIIb/IIIa inhibitors
differed among the included study cohorts (33–100%),
reﬂecting the development over time and a growing tendency
for application in selected patients only in the era of adequate
dual antiplatelet preloading. The choice for GPIIb/IIIa inhibitor
treatment is generally left to the discretion of the interven-
tional cardiologist and if patients received additional GPIIb/
IIIa inhibitors because microvascular injury was already
suspected based on suboptimal epicardial ﬂow restoration,
the effect of GPIIb/IIIa inhibitors on IMH might be an
overestimation. However, TIMI ﬂow <3 post-PCI was not
independently associated with presence or extent of IMH.
Also, in consideration of these possible sources of selection
bias, additional analyses were performed, as described in the
Results section, all supporting our conclusions.
Table 5. CMR Parameters of LV Function and Infarct Characteristics
No IMH
(n=188)
Mild IMH
(n=111)
Extensive IMH
(n=111)
P Value
No vs
Mild IMH
P Value
No vs
Extensive IMH
P Value
Mild vs
Extensive IMH
Infarct size, g 11.0 (4.1–21.1) 25.7 (16.7–35.2) 45.5 (32.9–57.4) <0.001 <0.001 <0.001
Infarct size, %LV 9.9 (3.6–17.8) 22.9 (16.9–30.6) 36.9 (29.1–45.4) <0.001 <0.001 <0.001
Presence of MVO, No. (%) 57 (31) 111 (100) 111 (100) <0.001 <0.001 NA
Extent of MVO, mL 0.9 (0.6–1.7) 1.7 (0.9–3.2) 6.6 (3.3–9.0) 0.001 <0.001 <0.001
Extent of MVO, %LV 0.85 (0.6–1.5) 1.7 (0.9–3.1) 5.1 (3.2–8.2) <0.001 <0.001 <0.001
LVEF 51 (9) 46 (8) 39 (8) <0.001 <0.001 <0.001
LVEDV, mL 166 (137–192) 167 (141–194) 188 (166–214) 0.56 <0.001 <0.001
LVEDVi, mL/m2 83 (74–97) 86 (73–98) 96 (88–107) 0.32 <0.001 <0.001
LVESV, mL 80 (64–99) 90 (72–110) 111 (95–137) 0.013 <0.001 <0.001
LVESVi, mL/m2 40 (34–50) 46 (37–56) 58 (50–67) 0.005 <0.001 <0.001
Data are presented as number (percentage) for dichotomous variables, meanSD for normally distributed continuous variables, and median (interquartile range) for non-normally
distributed continuous variables. CMR indicates cardiac magnetic resonance; IMH, intramyocardial hemorrhage; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEDVi,
indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; LVESVi, indexed left ventricular end-systolic volume; MVO,
microvascular obstruction; NA, not applicable.
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Furthermore, the METOCARD trial showed beneﬁt of
periprocedural b-blocker administration on infarct size and
MVO.28 No signiﬁcant differences in IMH occurrence (P=0.36)
or IMH extent (P=0.097) were found between patients with
and without intravenous periprocedural b-blockers in the
METOCARD trial. These data were not recorded in the other
studies and therefore b-blocker administration was not
included in our analysis.
As microvascular injury, including IMH, shows a dynamic
time course after STEMI, the timing of CMR imaging after PCI
(range 1–12 days) might have inﬂuenced the detection and
quantiﬁcation of IMH.29,30 We cannot exclude the possibility
that IMH was underestimated in some patients.
Lastly, in our study, T2-weighted CMR imaging was used
for IMH detection. There is no consensus yet on which
method should be preferred for IMH detection in patients with
STEMI, T2-weighted CMR imaging or T2*CMR imaging. T2*
sequences might be more sensitive and reliable in detecting
the presence of IMH31,32; however, spatial resolution is
generally poorer than in T2-weighted sequences, which limits
the quantiﬁcation of IMH extent. Until consensus has been
reached, both methods are frequently used to this end.
Conclusions
Additional GPIIb/IIIa inhibitor administration during PCI was
independently associated with development of IMH, which
warrants further investigation regarding the optimal applica-
tion of aggressive antithrombotic therapies. Anterior infarc-
tion was independently associated with occurrence of IMH
and higher risk of extensive IMH. These predictors might
prove useful in the future identiﬁcation of patients requiring
additional treatment during PCI. In agreement with previous
studies, IMH was associated with more severe infarction;
however, long-term follow-up is required to assess the relation
with functional and clinical outcome.
Acknowledgments
We thank the staff members of the catheterization laboratory, the
CMR imaging personnel, and the research nurses for their skilled
assistance during the various procedures.
Sources of Funding
The PREDICT-MVI study was supported in part by unrestricted
research grants from Volcano Corporation and Biotronik. The
METOCARD-CNIC was mainly sponsored by the CNIC through
competitive CNIC translational grant 012009 and by an
independent research grant from the Spanish National
Ministry of Health and Social Policy (EC10042), a Mutua
Madrile~na Foundation grant (AP86952011), and a master
research agreement between Philips Healthcare and CNIC. Dr
Ibanez is supported by competitive grants from the Institute of
Health Carlos III and the European Regional Development
Fund (ERDF/FEDER) (PI13/01979 and RD12/0042/0054).
Dr Fernandez-Jimenez holds a FICNIC fellowship from the
Fundacio Jesus Serra, the Fundacion Interhospitalaria de
Investigacion Cardiovascular (FIC), and the Centro Nacional
de Investigaciones Cardiovasculares Carlos III (CNIC). The
CNIC is supported by the MINECO and the Pro CNIC
Foundation, and is a Severo Ochoa Center of Excellence
(MINECO award SEV-2015-0505).
Disclosures
None.
References
1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA,
Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM,
Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-
Holland JE, Tommaso JE, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA
guideline for the management of ST-elevation myocardial infarction: executive
summary: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guidelines. Circulation.
2013;127:529–555.
2. Zhao B, Li J, Luo X, Zhou Q, Chen H, Shi H. The role of von Willebrand factor
and ADAMTS13 in the no-reﬂow phenomenon: after primary percutaneous
coronary intervention. Tex Heart Inst J. 2011;38:516–522.
3. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial
reperfusion injury: looking beyond primary PCI. Eur Heart J. 2013;34:1714–
1722.
4. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and
the no-reﬂow phenomenon after percutaneous coronary intervention. Circu-
lation. 2008;117:3152–3156.
5. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular
obstruction-related myocardial injury and coronary no-reﬂow following percu-
taneous coronary intervention: a systematic approach. JACC Cardiovasc Interv.
2010;3:695–704.
6. Betgem RP, de Waard GA, Nijveldt R, Beek AM, Escaned J, van Royen N.
Intramyocardial haemorrhage after acute myocardial infarction. Nat Rev
Cardiol. 2015;12:156–167.
7. Hamirani YS, Wong A, Kramer CM, Salerno M. Effect of microvascular
obstruction and intramyocardial hemorrhage by CMR on LV remodeling and
outcomes after myocardial infarction: a systematic review and meta-analysis.
JACC Cardiovasc Imaging. 2014;7:940–952.
8. Robbers LF, Eerenberg ES, Teunissen PF, Jansen MF, Hollander MR,
Horrevoets AJ, Knaapen P, Nijveldt R, Heymans MW, Levi MM, van Rossum
AC, Niessen HW, Marcu CB, Beek AM, van Royen N. Magnetic resonance
imaging-deﬁned areas of microvascular obstruction after acute myocardial
infarction represent microvascular destruction and haemorrhage. Eur Heart J.
2013;34:2346–2353.
9. Beek AM, Nijveldt R, van Rossum AC. Intramyocardial hemorrhage and
microvascular obstruction after primary percutaneous coronary intervention.
Int J Cardiovasc Imaging. 2010;26:49–55.
10. Eitel I, Kubusch K, Strohm O, Desch S, Mikami Y, de Waha S, Gutberlet M,
Schuler G, Friedrich MG, Thiele H. Prognostic value and determinants of a
hypointense infarct core in T2-weighted cardiac magnetic resonance in acute
reperfused ST-elevation-myocardial infarction. Circ Cardiovasc Imaging.
2011;4:354–362.
11. Husser O, Monmeneu JV, Sanchis J, Nunez J, Lopez-Lereu MP, Bonanad C,
Chaustre F, Gomez C, Bosch MJ, Hinarejos R, Chorro FJ, Riegger GA, Llacer A,
Bodi V. Cardiovascular magnetic resonance-derived intramyocardial hemor-
rhage after STEMI: inﬂuence on long-term prognosis, adverse left ventricular
remodeling and relationship with microvascular obstruction. Int J Cardiol.
2013;167:2047–2054.
DOI: 10.1161/JAHA.117.005651 Journal of the American Heart Association 9
Predictors of Intramyocardial Hemorrhage Amier et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 16, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
12. Teunissen PF, de Waard GA, Hollander MR, Robbers LF, Danad I, Biesbroek PS,
Amier RP, Echavarria-Pinto M, Quiros A, Broyd C, Heymans MW, Nijveldt R,
Lammertsma AA, Raijmakers PG, Allaart CP, Lemkes JS, Appelman YE,
Marques KM, Bronzwaer JG, Horrevoets AJ, van Rossum AC, Escaned J, Beek
AM, Knaapen P, van Royen N. Doppler-derived intracoronary physiology
indices predict the occurrence of microvascular injury and microvascular
perfusion deﬁcits after angiographically successful primary percutaneous
coronary intervention. Circ Cardiovasc Interv. 2015;8:e001786.
13. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR,
Twisk JW, van Rossum AC. Functional recovery after acute myocardial
infarction: comparison between angiography, electrocardiography, and car-
diovascular magnetic resonance measures of microvascular injury. J Am Coll
Cardiol. 2008;52:181–189.
14. Bekkers SC, Backes WH, Kim RJ, Snoep G, Gorgels AP, Passos VL,
Waltenberger J, Crijns HJ, Schalla S. Detection and characteristics of
microvascular obstruction in reperfused acute myocardial infarction using an
optimized protocol for contrast-enhanced cardiovascular magnetic resonance
imaging. Eur Radiol. 2009;19:2904–2912.
15. Ibanez B, Macaya C, Sanchez-Brunete V, Pizarro G, Fernandez-Friera L, Mateos
A, Fernandez-Ortiz A, Garcia-Ruiz JM, Garcia-Alvarez A, Iniguez A, Jimenez-
Borreguero J, Lopez-Romero P, Fernandez-Jimenez R, Goicolea J, Ruiz-Mateos B,
Bastante T, Arias M, Iglesias-Vazquez JA, Rodriguez MD, Escalera N, Acebal C,
Cabrera JA, Valenciano J, Perez de PA, Fernandez-Campos MJ, Casado I, Garcia-
Rubira JC, Garcia-Prieto J, Sanz-Rosa D, Cuellas C, Hernandez-Antolin R, Albarran
A, Fernandez-Vazquez F, de la Torre-Hernandez JM, Pocock S, Sanz G, Fuster V.
Effect of early metoprolol on infarct size in ST-segment-elevation myocardial
infarction patients undergoing primary percutaneous coronary intervention: the
effect of metoprolol in cardioprotection during an acute myocardial infarction
(METOCARD-CNIC) trial. Circulation. 2013;128:1495–1503.
16. Pizarro G, Fernandez-Friera L, Fuster V, Fernandez-Jimenez R, Garcia-Ruiz JM,
Garcia-Alvarez A, Mateos A, Barreiro MV, Escalera N, Rodriguez MD, de Miguel
A, Garcia-Lunar I, Parra-Fuertes JJ, Sanchez-Gonzalez J, Pardillos L, Nieto B,
Jimenez A, Abejon R, Bastante T, Martinez de Vega V, Cabrera JA, Lopez-
Melgar B, Guzman G, Garcia-Prieto J, Mirelis JG, Zamorano JL, Albarran A,
Goicolea J, Escaned J, Pocock S, Iniguez A, Fernandez-Ortiz A, Sanchez-Brunete
V, Macaya C, Ibanez B. Long-term beneﬁt of early pre-reperfusion metoprolol
administration in patients with acute myocardial infarction: results from the
METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an
acute myocardial infarction). J Am Coll Cardiol. 2014;63:2356–2362.
17. Ibanez B, Fuster V, Macaya C, Sanchez-Brunete V, Pizarro G, Lopez-Romero P,
Mateos A, Jimenez-Borreguero J, Fernandez-Ortiz A, Sanz G, Fernandez-Friera
L, Corral E, Barreiro MV, Ruiz-Mateos B, Goicolea J, Hernandez-Antolin R,
Acebal C, Garcia-Rubira JC, Albarran A, Zamorano JL, Casado I, Valenciano J,
Fernandez-Vazquez F, de la Torre JM, de Perez PA, Iglesias-Vazquez JA,
Martinez-Tenorio P, Iniguez A. Study design for the “effect of metoprolol in
cardioprotection during an acute myocardial infarction” (METOCARD-CNIC): a
randomized, controlled parallel-group, observer-blinded clinical trial of early
pre-reperfusion metoprolol administration in ST-segment elevation myocardial
infarction. Am Heart J. 2012;164:473–480.
18. Carrick D, Haig C, Rauhalammi S, Ahmed N, Mordi I, McEntegart M, Petrie MC,
Eteiba H, Hood S, Watkins S, Lindsay M, Mahrous A, Ford I, Tzemos N, Sattar
N, Welsh P, Radjenovic A, Oldroyd KG, Berry C. Prognostic signiﬁcance of
infarct core pathology revealed by quantitative non-contrast in comparison
with contrast cardiac magnetic resonance imaging in reperfused ST-elevation
myocardial infarction survivors. Eur Heart J. 2016;37:1044–1059.
19. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van de
Werf F, Bogaert J. Impact of myocardial haemorrhage on left ventricular
function and remodelling in patients with reperfused acute myocardial
infarction. Eur Heart J. 2009;30:1440–1449.
20. Carrick D, Haig C, Ahmed N, McEntegart M, Petrie MC, Eteiba H, Hood S,
Watkins S, Lindsay MM, Davie A, Mahrous A, Mordi I, Rauhalammi S, Sattar N,
Welsh P, Radjenovic A, Ford I, Oldroyd KG, Berry C. Myocardial hemorrhage
after acute reperfused ST-segment-elevation myocardial infarction: relation to
microvascular obstruction and prognostic signiﬁcance. Circ Cardiovasc
Imaging. 2016;9:e004148.
21. Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH,
Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ, Chowdhary S, El-Omar M,
Neunteuﬂ T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM.
Intracoronary abciximab and aspiration thrombectomy in patients with large
anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA.
2012;307:1817–1826.
22. Thiele H, Wohrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P,
Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler
G. Intracoronary versus intravenous bolus abciximab during primary percuta-
neous coronary intervention in patients with acute ST-elevation myocardial
infarction: a randomised trial. Lancet. 2012;379:923–931.
23. Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De LG.
Clinical efﬁcacy and safety of intracoronary vs. intravenous abciximab
administration in STEMI patients undergoing primary percutaneous coronary
intervention: a meta-analysis of randomized trials. Platelets. 2012;23:274–
281.
24. Witkowski A, Maciejewski P, Wasek W, Malek LA, Niewada M, Kaminski B,
Drzewiecki J, Kosmider M, Kubica J, Ruzyllo W, Peruga JZ, Dudek D, Opolski G,
Dobrzycki S, Gil RJ; Collaborators SR. Inﬂuence of different antiplatelet
treatment regimens for primary percutaneous coronary intervention on all-
cause mortality. Eur Heart J. 2009;30:1736–1743.
25. Buszman PP, Wojakowski W, Milewski K, Debinski M, Pajak J, Aboodi MS,
Jackiewicz W, Kawka M, Bochenek A, Prats J, Granada JF, Kaluza GL, Buszman
PE. Controlled reperfusion with intravenous bivalirudin and intracoronary
abciximab combination therapy in the porcine myocardial infarction model.
Thromb Res. 2012;130:265–272.
26. Malek LA, Klopotowski M, Spiewak M, Wozniak K, Was J, Misko J, Ruzyllo W,
Witkowski A. Platelet reactivity and intramyocardial hemorrhage in patients
with ST-segment elevation myocardial infarction. Clin Appl Thromb Hemost.
2014;20:553–558.
27. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med.
2007;356:830–840.
28. Garcia-Prieto J, Villena-Gutierrez R, Gomez M, Bernardo E, Pun-Garcia A,
Garcia-Lunar I, Crainiciuc G, Fernandez-Jimenez R, Sreeramkumar V, Bourio-
Martinez R, Garcia-Ruiz JM, Serrano del Valle A, Sanz-Rosa D, Pizarro G,
Fernandez-Ortiz A, Hidalgo A, Fuster V, Ibanez B. Neutrophil stunning by
metoprolol reduces infarct size. Nat Commun. 2017;8:14780.
29. Carrick D, Haig C, Ahmed N, Rauhalammi S, Clerfond G, Carberry J, Mordi I,
McEntegart M, Petrie MC, Eteiba H, Hood S, Watkins S, Lindsay MM, Mahrous
A, Welsh P, Sattar N, Ford I, Oldroyd KG, Radjenovic A, Berry C. Temporal
evolution of myocardial hemorrhage and edema in patients after acute ST-
segment elevation myocardial infarction: pathophysiological insights and
clinical implications. J Am Heart Assoc. 2016;5:e002834. 10.1161/JAHA.115.
002834.
30. Fernandez-Jimenez R, Garcia-Prieto J, Sanchez-Gonzalez J, Aguero J, Lopez-
Martin GJ, Galan-Arriola C, Molina-Iracheta A, Doohan R, Fuster V, Ibanez B.
Pathophysiology underlying the bimodal edema phenomenon after myocardial
ischemia/reperfusion. J Am Coll Cardiol. 2015;66:816–828.
31. Kandler D, Lucke C, Grothoff M, Andres C, Lehmkuhl L, Nitzsche S, Riese F,
Mende M, de Waha S, Desch S, Lurz P, Eitel I, Gutberlet M. The relation
between hypointense core, microvascular obstruction and intramyocardial
haemorrhage in acute reperfused myocardial infarction assessed by cardiac
magnetic resonance imaging. Eur Radiol. 2014;24:3277–3288.
32. Hansen ES, Pedersen SF, Pedersen SB, Kjaergaard U, Schmidt NH, Botker HE,
Kim WY. Cardiovascular MR T2-STIR imaging does not discriminate between
intramyocardial haemorrhage and microvascular obstruction during the
subacute phase of a reperfused myocardial infarction. Open Heart. 2016;3:
e000346.
DOI: 10.1161/JAHA.117.005651 Journal of the American Heart Association 10
Predictors of Intramyocardial Hemorrhage Amier et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 16, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Smulders, Sebastiaan C. A. M. Bekkers, Niels van Royen, Borja Ibanez and Robin Nijveldt
Pizarro, Inés García-Lunar, Teresa Bastante, Peter M. van de Ven, Aernout M. Beek, Martijn W. 
Raquel P. Amier, Ruben Y. G. Tijssen, Paul F. A. Teunissen, Rodrigo Fernández-Jiménez, Gonzalo
Myocardial Infarction
Segment Elevation−Predictors of Intramyocardial Hemorrhage After Reperfused ST
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.005651
2017;6:e005651; originally published August 15, 2017;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/6/8/e005651
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on O
ctober 16, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
